Molecular Advances in Platelet Disease, Thrombosis and Hemostasis

Dear Colleagues,

Hemostasis is a tightly regulated physiological process that prevents excessive bleeding while maintaining vascular integrity. It involves a complex interaction between the vascular endothelium, platelets, and the coagulation cascade, ultimately leading to the formation of a stable hemostatic plug. When dysregulated, this process can result in thrombosis, a pathological condition characterized by the formation of occlusive blood clots. Thrombosis is a major global health concern, contributing to life-threatening conditions such as myocardial infarction, stroke, and venous thromboembolism. Despite significant therapeutic advances, thrombotic disorders remain a leading cause of morbidity and mortality worldwide.

Platelets play a central role in hemostasis and thrombosis, responding rapidly to vascular injury by forming aggregates to prevent hemorrhage. Their crucial function in hemostasis is well demonstrated in patients with inherited platelet disorders (IPD), who often experience severe bleeding tendencies and other clinical complications. Understanding the molecular causes of these diseases, along with improving early diagnosis, is essential for optimizing patient management and enhancing their quality of life. Early detection of platelet dysfunctions allows for timely medical interventions, reducing the risk of severe hemorrhagic or thrombotic events.

Antiplatelet therapies are widely used to mitigate thrombotic risk, yet they often pose a trade-off between efficacy and bleeding complications. Advances in platelet biology, including multi-omics and proteomic approaches, have provided critical insights into platelet activation, signaling pathways, and post-translational modifications such as phosphorylation and proteolysis. Additionally, a deeper molecular understanding of the interplay between platelets, coagulation, innate immunity, and cancer is essential for developing safer and more effective diagnostic and therapeutic strategies in bleeding and thrombotic diseases.

We are launching this Special Issue of Biomolecules to explore important aspects in this field, such as the practical approach to the diagnosis of IPD, expanding the genetic spectrum of these diseases, and uncovering new molecular and cellular mechanisms in thrombosis and its management.

We look forward to receiving your contributions to making this initiative a wonderful and comprehensive Special Issue.

Dr. José Rivera
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• platelets
• hemostasis and thrombosis
• inherited platelet disorders
• coagulation
• immunothrombosis
• miRNA
• GPVI
• Runx1
• antiplatelet therapy